SG Americas Securities
RCUS icon

SG Americas Securities’s Arcus Biosciences RCUS Stock Holding History

SG Americas Securities’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.16M Sell
37,765
-4,290
-10% -$106K ﹤0.01% 1781
2026
Q1 		$908K Sell
42,055
-3,433
-8% -$74.1K ﹤0.01% 1815
2025
Q4 		$1.08M Buy
45,488
+12,714
+39% +$259K ﹤0.01% 1943
2025
Q3 		$446K Buy
32,774
+5,412
+20% +$56.3K ﹤0.01% 2203
2025
Q2 		$223K Buy
27,362
+17,111
+167% +$146K ﹤0.01% 2200
2025
Q1 		$80K Sell
10,251
-18,246
-64% -$212K ﹤0.01% 3113
2024
Q4 		$424K Sell
28,497
-1,572
-5% -$25.7K ﹤0.01% 1485
2024
Q3 		$460K Sell
30,069
-99,223
-77% -$1.56M ﹤0.01% 1759
2024
Q2 		$1.97M Buy
129,292
+120,650
+1,396% +$1.95M 0.01% 959
2024
Q1 		$163K Sell
8,642
-11,926
-58% -$206K ﹤0.01% 2132
2023
Q4 		$393K Buy
+20,568
New +$329K ﹤0.01% 1636
2023
Q2 		– Sell
-12,184
Closed -$222K – 3002
2023
Q1 		$222K Sell
12,184
-19,605
-62% -$375K ﹤0.01% 2345
2022
Q4 		$657K Buy
+31,789
New +$875K 0.01% 1308
2022
Q3 		– Sell
-37,557
Closed -$952K – 3482
2022
Q2 		$952K Sell
37,557
-56,629
-60% -$1.39M 0.01% 1344
2022
Q1 		$2.97M Buy
94,186
+68,297
+264% +$2.29M 0.02% 669
2021
Q4 		$1.05M Sell
25,889
-1,201
-4% -$46.6K 0.01% 1618
2021
Q3 		$945K Buy
+27,090
New +$843K ﹤0.01% 1964
2021
Q2 		– Sell
-7,201
Closed -$202K – 3171
2021
Q1 		$202K Sell
7,201
-4,668
-39% -$162K ﹤0.01% 2676
2020
Q4 		$308K Sell
11,869
-20,657
-64% -$500K ﹤0.01% 2345
2020
Q3 		$557K Buy
32,526
+17,863
+122% +$399K ﹤0.01% 1559
2020
Q2 		$363K Buy
14,663
+2,965
+25% +$80K ﹤0.01% 2372
2020
Q1 		$162K Buy
+11,698
New +$145K ﹤0.01% 2660
2019
Q2 		– Sell
-8,782
Closed -$110K – 3353
2019
Q1 		$110K Buy
+8,782
New +$95.3K ﹤0.01% 3001

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

SG Americas Securities's RCUS Position: Q2 2026 in Review

SG Americas Securities reduced its Arcus Biosciences (RCUS) stake by 10% in Q2 2026, selling an estimated $106K and leaving 37,765 shares worth $1.16M. The position accounts for ﹤0.01% of the portfolio, ranked #1781.

SG Americas Securities first reported a position in RCUS in Q1 2019 and has held it in 23 quarters since. The position peaked at $2.97M in Q1 2022. 231 funds tracked by Wall St. Rank hold RCUS as of Q2 2026.

  • SG Americas Securities held 37,765 shares of Arcus Biosciences worth $1.16M as of Q2 2026.
  • SG Americas Securities sold 4,290 Arcus Biosciences shares in Q2 2026, an estimated $106K.
  • Arcus Biosciences made up ﹤0.01% of SG Americas Securities's portfolio in Q2 2026, its #1781 holding.
  • SG Americas Securities first reported a position in Arcus Biosciences in Q1 2019 and has held it in 23 quarters since.
  • SG Americas Securities's Arcus Biosciences position peaked at $2.97M in Q1 2022.
  • 231 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2026.

Based on SG Americas Securities's 13F filing for Q2 2026, filed 7 Aug 2026.